Phase II Study of Lenalidomide Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Mar 2018
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 27 Feb 2018 Planned End Date changed from 1 Oct 2020 to 1 Oct 2022.
- 12 Dec 2017 Results of 5-year follow-up and correlative exploratory analysis of immunologic biomarkers and minimal residual disease measurement, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
- 23 Feb 2017 Planned End Date changed from 1 Oct 2018 to 1 Oct 2020.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History